ArticleImaging neuroscience (Cambridge, Mass.)2025
Novel insights into vascular dysfunction in cuprizone-induced demyelination through functional ultrasound imaging.
Article in Imaging neuroscience (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), affecting 2.8 million people worldwide, that presents multiple features, one of which is demyelination. Although treatments exist to manage the condition, no cure has been found to stop the progression of neurodegeneration. To develop new treatments and investigate the multiple systems impacted by MS, new imaging technologies are needed at the preclinical stage. Functional ultrasound imaging (fUS) has recently emerged as a robust method to measure brain cerebral blood volume (CBV) dynamics as an indirect indicator of neural activity. This study aimed to quantify the amplitude of alteration of evoked hemodynamic response in the somatosensory cortex, and its potential link with demyelination in a mouse model of CNS demyelination induced by cuprizone. We demonstrate that extended demyelination leads to an increased hemodynamic response in the primary sensory cortex, both spatially and temporally, aligning with fMRI findings in MS patients. Second, using descriptors of the evoked cortical hemodynamic response, we demonstrate that certain parameters (the number of active pixels and the rise time) correlate with the level of Myelin Basic Protein in the primary sensory cortex and the thalamus, when taken together. Interestingly, the increased CBV is not associated with demyelination but instead reflects the well-documented vascular alteration described in MS. Moreover, these changes were absent in the thalamus, and in focalized demyelinated lesions induced by lysolecithin injection, suggesting the involvement of specific cortical mechanisms driven by oligodendrocyte depletion. In conclusion, our study introduces a novel, non-invasive functional approach for investigating vascular dysfunction in the context of MS, addressing an important yet understudied aspect in both pre-clinical and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.